



Press Release


STADA strengthens CHC local hero brand portfolio by acquiring Locobase derma line in Nordics

- STADA strengthens Consumer Healthcare presence in Nordic countries by acquiring rights to Locobase[®] dermatology brand
- Locobase[®] range of 17 products complements STADA's strong CHC skincare offering
- STADA Head of Global Consumer Healthcare, Volker Sydow: "Locobase[®] is a derma brand loved by Nordic consumers that further strengthens our portfolio of local hero brands in Scandinavia. We see considerable potential to accelerate Locobase[®]'s growth momentum by optimizing its marketing mix and applying the dedicated focus of our STADA Nordics team."

Bad Vilbel, Germany – 4 May 2026 – STADA has reinforced its status as a partner of choice and top-five player in European consumer healthcare by acquiring commercial rights to the Locobase[®] skincare range in Denmark, Sweden, Norway, Finland and Iceland. The vendor, Karo Healthcare, retains rights elsewhere. No financial details were disclosed.

Locobase[®] is a top-five brand in the dry skin market across Nordic markets, and ranks second in its home market, Denmark. The specialist skin brand comprises a broad portfolio addressing the needs of consumers with dry, sensitive or barrier-impaired skin, including products that are used as part of the care and management of conditions such as eczema or psoriasis. Spanning medical devices, cosmetics and OTC medicines, the range comprises 17 presentations or stock-keeping units (SKUs) that are supplied predominantly through pharmacies.

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au




“Locobase® is highly complementary to both our consumer healthcare offering in Nordic countries and our extensive skincare portfolio globally,” commented Volker Sydow, STADA’s Head of Global Consumer Healthcare. “Locobase® is a derma brand loved by Nordic consumers that further strengthens our portfolio of local hero brands in Scandinavia. We see considerable potential to accelerate Locobase®’s growth momentum by optimizing its marketing mix and applying the dedicated focus of our STADA Nordics team.”

With Locobase® having achieved a double-digit compound annual growth rate (CAGR) in sales between 2023 and 2025, STADA is confident that the brand offers further growth potential across the entire region. The brand is highly complementary to STADA Nordics’ existing portfolio of local hero brands in skin and scalp care that includes: Ceridal® creams and lotions, Dermalog® lipid-based moisturisers; the Flexitol® foot and heel care line; Hedrin® head-lice treatments; and Nizoral® anti-dandruff products.¹

Locobase® is positioned around the repair, protection, renewal and calming of the skin barrier; a central pathophysiological concept in conditions such as atopic dermatitis, eczema and psoriasis. The brand’s 17 presentations are grouped into four segments – Repair, Protect, Renew and Calm – enabling pharmacists and healthcare professionals to tailor recommendations to individual needs of consumers and their dependents.

¹ [Products | STADA Nordic](#)

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler
Chairman of the Supervisory Board: Dr. Günter von Au



About STADA Group

The STADA Group is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 961 million. As of 31 December 2025, STADA employed 11,670 people worldwide.

Additional information for journalists

STADA Arzneimittel AG - Media Relations

Stadastrasse 2-18, 61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165

E-Mail: press@stada.com

Or visit us via our website at <https://www.stada.com/media/newsroom>

Follow [@StadaGroup](#) on LinkedIn

Additional information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18, 61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us via our website at <https://www.stada.com/investor-relations/>

Executive Board: Peter Goldschmidt (CEO) / Miguel Pagan Fernandez / Boris Döbler

Chairman of the Supervisory Board: Dr. Günter von Au